Movatterモバイル変換

[0]ホーム
URL:

IN2014CN03597A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03597A
IN2014CN03597AIN3597CHN2014AIN2014CN03597AIN 2014CN03597 AIN2014CN03597 AIN 2014CN03597AIN 3597CHN2014 AIN3597CHN2014 AIN 3597CHN2014AIN 2014CN03597 AIN2014CN03597 AIN 2014CN03597A
Authority
IN
India
Prior art keywords
compounds
compositions
pdgfrß
csfir
treatment
Prior art date
Application number
Inventor
Michael J Hadd
Michael D Hocker
Mark W Holladay
Gang Liu
Martin W Rowbottom
Shimin Xu
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences CorpfiledCriticalAmbit Biosciences Corp
Publication of IN2014CN03597ApublicationCriticalpatent/IN2014CN03597A/en

Links

Classifications

Landscapes

Abstract

Provided herein are heterocyclic compounds for treatment of CSFIR FLT3 KIT and/or PDGFRß kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
IN3597CHN20142011-10-142012-10-12IN2014CN03597A (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201161547637P2011-10-142011-10-14
US201261638990P2012-04-262012-04-26
PCT/US2012/059983WO2013056070A2 (en)2011-10-142012-10-12Heterocyclic compounds and methods of use thereof

Publications (1)

Publication NumberPublication Date
IN2014CN03597Atrue IN2014CN03597A (en)2015-10-09

Family

ID=47116440

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN3597CHN2014IN2014CN03597A (en)2011-10-142012-10-12

Country Status (29)

CountryLink
US (3)US8952058B2 (en)
EP (1)EP2766359B9 (en)
JP (1)JP6162130B2 (en)
KR (1)KR102066297B1 (en)
CN (1)CN104066730B (en)
AR (1)AR089568A1 (en)
AU (1)AU2012322095B2 (en)
BR (1)BR112014009006B8 (en)
CA (1)CA2851155C (en)
CY (1)CY1117745T1 (en)
DK (1)DK2766359T5 (en)
ES (1)ES2586527T3 (en)
HR (1)HRP20160744T2 (en)
HU (1)HUE027745T4 (en)
IL (1)IL231927A (en)
IN (1)IN2014CN03597A (en)
MX (1)MX368081B (en)
MY (1)MY167575A (en)
PH (2)PH12014500794A1 (en)
PL (1)PL2766359T3 (en)
PT (1)PT2766359T (en)
RS (1)RS54936B1 (en)
RU (1)RU2648997C2 (en)
SG (1)SG11201401236XA (en)
SI (1)SI2766359T1 (en)
SM (1)SMT201600223B (en)
TW (2)TWI605043B (en)
WO (1)WO2013056070A2 (en)
ZA (1)ZA201402549B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2014031445A1 (en)*2012-08-222014-02-27Merck Sharp & Dohme Corp.Novel benzimidazole tetrahydropyran derivatives
AR097543A1 (en)*2013-09-062016-03-23Lexicon Pharmaceuticals Inc COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE
PL3466955T3 (en)2014-01-132021-06-28Aurigene Discovery Technologies Limited The method of obtaining oxazolo [4,5-B] pyridine and thiazolo [4,5-B] pyridine derivatives as inhibitors of IRAK4 in the treatment of cancer
JP6898914B2 (en)*2015-07-202021-07-07ジェンザイム・コーポレーション Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor
CA3007168A1 (en)*2015-12-142017-06-22Zenith Epigenetics Ltd.1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
MA44611A (en)*2016-04-042019-02-13Massachusetts Inst Technology COMPOSITIONS OF HYDROPHOBIC CRYSTALLIZED COMPOUNDS AND THEIR PREPARATION AND USE METHODS
US11712480B2 (en)2016-08-032023-08-01Pfizer Inc.Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
MX2019004822A (en)2016-11-142019-09-11Jiangsu Hengrui Medicine Co3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof.
US11299480B2 (en)2017-01-232022-04-12University Of Hawaii2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors
IL269536B (en)*2017-03-312022-07-01Aurigene Discovery Tech Ltd Compounds and preparations for the treatment of hematological disorders
CN112040947A (en)2017-12-072020-12-04密歇根大学董事会NSD family inhibitors and methods of treatment therewith
US20210317461A1 (en)2018-08-092021-10-14Verseau Therapeutics, Inc.Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN112480101B (en)*2019-09-122022-11-25中国科学院上海药物研究所IRAK4 kinase inhibitor, preparation and application thereof
CN112479897B (en)*2020-12-072022-11-04万华化学集团股份有限公司Preparation process of 1, 3-cyclohexyldimethylamine
JP2024500919A (en)2020-12-232024-01-10ジェンザイム・コーポレーション Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitor
EP4319750A4 (en)2021-04-082025-02-26Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN117384110A (en)*2023-10-162024-01-12奥盖尼克材料(苏州)有限公司Preparation method of 2-aminobenzoxazole-6-nitrile

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3536809A (en)1969-02-171970-10-27Alza CorpMedication method
US3598123A (en)1969-04-011971-08-10Alza CorpBandage for administering drugs
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916899A (en)1973-04-251975-11-04Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4104385A (en)1976-08-191978-08-01Sterling Drug Inc.Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates
KR890002631B1 (en)1984-10-041989-07-21몬산토 캄파니Composition of prolonged release of biologically active somatotropin
IE58110B1 (en)1984-10-301993-07-14Elan Corp PlcControlled release powder and process for its preparation
US5073543A (en)1988-07-211991-12-17G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en)1989-03-221991-07-25Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en)1989-07-071997-12-23Novartis IncSustained release formulations of water soluble peptides.
US5120548A (en)1989-11-071992-06-09Merck & Co., Inc.Swelling modulated polymeric drug delivery device
US5585112A (en)1989-12-221996-12-17Imarx Pharmaceutical Corp.Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en)1990-04-171994-11-18Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5733566A (en)1990-05-151998-03-31Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
US5543390A (en)1990-11-011996-08-06State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityCovalent microparticle-drug conjugates for biological targeting
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687932A1 (en)1992-02-271993-09-03Oreal OIL-IN-WATER DISPERSION CAPABLE OF FORMING COMPOSITE FILMS.
TW333456B (en)1992-12-071998-06-11Takeda Pharm Ind Co LtdA pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en)1993-01-251997-01-07Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en)1993-03-182001-08-14Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factors
US5985307A (en)1993-04-141999-11-16Emory UniversityDevice and method for non-occlusive localized drug delivery
US5523092A (en)1993-04-141996-06-04Emory UniversityDevice for local drug delivery and methods for using the same
US6087324A (en)1993-06-242000-07-11Takeda Chemical Industries, Ltd.Sustained-release preparation
US6004534A (en)1993-07-231999-12-21Massachusetts Institute Of TechnologyTargeted polymerized liposomes for improved drug delivery
IT1270594B (en)1994-07-071997-05-07Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5759542A (en)1994-08-051998-06-02New England Deaconess Hospital CorporationCompositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en)1994-11-281997-08-26Haynes; Duncan HDrug releasing surgical implant or dressing material
US6316652B1 (en)1995-06-062001-11-13Kosta SteliouDrug mitochondrial targeting agents
DE69632684T2 (en)1995-06-272005-06-09Takeda Pharmaceutical Co. Ltd. PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS
TW448055B (en)1995-09-042001-08-01Takeda Chemical Industries LtdMethod of production of sustained-release preparation
JP2909418B2 (en)1995-09-181999-06-23株式会社資生堂 Delayed release microsphere of drug
US6039975A (en)1995-10-172000-03-21Hoffman-La Roche Inc.Colon targeted delivery system
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
TW345603B (en)1996-05-291998-11-21Gmundner Fertigteile GmbhA noise control device for tracks
US6264970B1 (en)1996-06-262001-07-24Takeda Chemical Industries, Ltd.Sustained-release preparation
US6419961B1 (en)1996-08-292002-07-16Takeda Chemical Industries, Ltd.Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en)1996-10-012000-08-28Stanford Res Inst IntTaste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en)1996-10-091998-04-09Sumitomo Pharmaceuticals Co., Ltd.Sustained release formulation
DE69730093T2 (en)1996-10-312006-07-20Takeda Pharmaceutical Co. Ltd. Preparation with delayed release
US6131570A (en)1998-06-302000-10-17Aradigm CorporationTemperature controlling device for aerosol drug delivery
US6197350B1 (en)1996-12-202001-03-06Takeda Chemical Industries, Ltd.Method of producing a sustained-release preparation
US5891474A (en)1997-01-291999-04-06Poli Industria Chimica, S.P.A.Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en)1997-03-212000-09-19Imarx Pharmaceutical Corp.Charged lipids and uses for the same
US6060082A (en)1997-04-182000-05-09Massachusetts Institute Of TechnologyPolymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
ES2256969T3 (en)*1997-11-102006-07-16Bristol-Myers Squibb Company INHIBITING BENZOTIAZOL PROTEIN TIROSINE QAUINASA COMPOUNDS.
WO1999036099A1 (en)1998-01-161999-07-22Takeda Chemical Industries, Ltd.Sustained release compositions, process for producing the same and utilization thereof
US6613358B2 (en)1998-03-182003-09-02Theodore W. RandolphSustained-release composition including amorphous polymer
US6048736A (en)1998-04-292000-04-11Kosak; Kenneth M.Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (en)1998-05-161999-12-06허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US6248363B1 (en)1999-11-232001-06-19Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en)1999-04-142001-08-07Musc Foundation For Research DevelopmentTissue-specific and pathogen-specific toxic agents and ribozymes
MXPA02007632A (en)*2000-02-072004-08-23Abbott Gmbh & Co Kg2 benzothiazolyl urea derivatives and their use as protein kinase inhibitors.
ATE383858T1 (en)*2001-06-062008-02-15Aventis Pharma Ltd SUBSTITUTED TETRHYDROISOCINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7112435B1 (en)2002-08-072006-09-26Ambit Biosciences CorporationUncoupling of DNA insert propagation and expression of protein for phage display
AU2003231359B2 (en)*2002-04-162009-04-30Teijin LimitedPiperidine derivatives having CCR3 antagonism
FR2851563B1 (en)2003-02-262005-04-22Sod Conseils Rech Applic NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
TWI344955B (en)2003-03-142011-07-11Ono Pharmaceutical CoHeterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7531553B2 (en)*2003-03-212009-05-12Amgen Inc.Heterocyclic compounds and methods of use
JPWO2005040135A1 (en)2003-10-242007-03-08小野薬品工業株式会社 Anti-stress drugs and their medicinal uses
DE10349587A1 (en)2003-10-242005-05-25Merck Patent Gmbh Benzimidazolylderivate
AR046959A1 (en)2003-12-182006-01-04Tibotec Pharm Ltd MORFOLINILO CONTAINING BENCIMIDAZOLS AS INHIBITORS OF THE REPLICATION OF RESPIRATORY SYNTHETIC VIRUSES
EP1697347B1 (en)2003-12-182011-02-23Tibotec Pharmaceuticals5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US7470712B2 (en)2004-01-212008-12-30Bristol-Myers Squibb CompanyAmino-benzazoles as P2Y1 receptor inhibitors
WO2005100373A2 (en)*2004-04-132005-10-27Ranbaxy Laboratories LimitedMonosaccharide derivatives as anti-cancer and anti-inflammatory agents
US6969498B1 (en)*2004-05-072005-11-29Riley Medical, Inc.Surgical instrument bracket assembly
JP2006070014A (en)2004-08-042006-03-16Hisamitsu Medical Kk 2-aminobenzothiazole derivatives
ATE529424T1 (en)2005-06-202011-11-15Tibotec Pharm Ltd 1-ÄÄ2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYLÜMETHYLÜ-3-SUBSTITUTED-1,3-DIHYDROBENZIMIDAZOL-2-ONE AS A REPLICATION INHIBITOR OF THE RESPIRATORY SYNCYTIAL VIRUS
WO2007022305A2 (en)2005-08-162007-02-22Pharmacopeia, Inc.2-aminoimidazopyridines for treating neurodegenerative diseases
PT2001892E (en)*2006-03-172013-07-04Ambit Biosciences CorpImidazolothiazole compounds for the treatment of proliferative diseases
US8394842B2 (en)*2006-03-282013-03-12High Point Pharmaceuticals, LlcBenzothiazoles having histamine H3 receptor activity
KR20090034930A (en)2006-06-302009-04-08암비트 바이오사이언시즈 코포레이션 Detectable Nucleic Acid Tags
US20100144751A1 (en)2007-03-282010-06-10Array Biopharma Inc.IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CN101754965B (en)*2007-05-212014-03-19诺华股份有限公司CSF-1R inhibitors, compositions, and methods of use
CA2702699A1 (en)*2007-10-182009-04-23Novartis AgCsf-1r inhibitors compositions, and mthods of use
US8153813B2 (en)2007-12-202012-04-10Abbott LaboratoriesBenzothiazole and benzooxazole derivatives and methods of use
US8309577B2 (en)*2008-04-232012-11-13Bristol-Myers Squibb CompanyQuinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en)*2008-04-232011-01-04Bristol-Myers Squibb CompanyQuinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
HUE035798T2 (en)2008-11-032018-05-28Syntarga BvCc-1065 analogs and their conjugates
UY32470A (en)*2009-03-052010-10-29Boehringer Ingelheim Int DERIVATIVES OF 2- {2-CHLORINE-5 - [(REPLACED) METHYL] PHENYLAMINE} -1-METHYL] PHENYLAMINE} -1-METHYLBENCIMIDAZOL-5-CARBOXAMIDES-N- (SUBSTITUTED) AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, COMPOSITIONS AND APPLIANCE
CA2800664C (en)2010-06-012019-09-24Angion Biomedica Corp.Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
US9115127B2 (en)2010-08-052015-08-25Amgen Inc.Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
US8987271B2 (en)2010-12-222015-03-24Eutropics Pharmaceuticals, Inc.2,2′-biphenazine compounds and methods useful for treating disease

Also Published As

Publication numberPublication date
MX2014004252A (en)2014-06-11
CN104066730A (en)2014-09-24
HRP20160744T2 (en)2017-08-11
PT2766359T (en)2016-07-14
BR112014009006B8 (en)2022-05-31
US9938261B2 (en)2018-04-10
MY167575A (en)2018-09-20
TW201811777A (en)2018-04-01
BR112014009006A2 (en)2017-04-18
EP2766359B1 (en)2016-04-13
TWI605043B (en)2017-11-11
IL231927A (en)2017-01-31
JP6162130B2 (en)2017-07-12
EP2766359B9 (en)2017-04-05
ZA201402549B (en)2015-08-26
HUE027745T2 (en)2016-10-28
US9452167B2 (en)2016-09-27
WO2013056070A2 (en)2013-04-18
TWI650321B (en)2019-02-11
AU2012322095B2 (en)2017-06-29
PH12014500794B1 (en)2014-10-20
SI2766359T1 (en)2016-09-30
ES2586527T9 (en)2017-06-19
DK2766359T5 (en)2017-06-26
SMT201600223B (en)2016-08-31
AU2012322095A1 (en)2014-04-17
ES2586527T3 (en)2016-10-17
RU2648997C2 (en)2018-03-29
PH12014500794A1 (en)2014-10-20
US20130096113A1 (en)2013-04-18
KR20140075010A (en)2014-06-18
HRP20160744T1 (en)2016-09-23
AR089568A1 (en)2014-09-03
DK2766359T3 (en)2016-07-25
TW201321376A (en)2013-06-01
RU2014119244A (en)2015-11-20
HK1200814A1 (en)2015-08-14
EP2766359A2 (en)2014-08-20
US8952058B2 (en)2015-02-10
US20160362405A1 (en)2016-12-15
BR112014009006B1 (en)2022-05-17
KR102066297B1 (en)2020-01-14
WO2013056070A3 (en)2013-08-01
PH12015501955B1 (en)2018-03-19
MX368081B (en)2019-09-19
CA2851155A1 (en)2013-04-18
CN104066730B (en)2017-03-08
SG11201401236XA (en)2014-05-29
RS54936B1 (en)2016-11-30
CA2851155C (en)2021-02-23
US20150196566A1 (en)2015-07-16
JP2014528482A (en)2014-10-27
HUE027745T4 (en)2017-09-28
IL231927A0 (en)2014-05-28
PL2766359T3 (en)2016-11-30
CY1117745T1 (en)2017-05-17
NZ623274A (en)2016-05-27
PH12015501955A1 (en)2018-03-19

Similar Documents

PublicationPublication DateTitle
IN2014CN03597A (en)
MX2012001974A (en)Biaryl compounds and methods of use thereof.
TN2012000465A1 (en)Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2021001231A (en)Heterocyclic compounds and their uses.
IN2015DN01156A (en)
MX346375B (en)Spiro-oxindole mdm2 antagonists.
MY193728A (en)Muscarinic receptor agonists
MX2014012695A (en)Isoindolone derivatives.
PH12013501821A1 (en)Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
ME03042B (en)Compounds and compositions for the treatment of parasitic diseases
EA201270722A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
PH12013501754A1 (en)Triazolopyridine compounds as pim kinase inhibitors
MX2013010898A (en)Novel pyrimidine derivatives.
IN2015DN01119A (en)
MX2015012416A (en)Heterocyclic compounds and their uses.
WO2011150201A3 (en)Azolyl amide compounds and methods of use thereof
PH12017500089B1 (en)Aldosterone synthase inhibitors
MX2017004852A (en)Aldosterone synthase inhibitors.
GB201213484D0 (en)Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
IN2015DN02109A (en)
AU2011900519A0 (en)Drug compositions for the treatment of insomnia
UA110793C2 (en)Pyrazolyl hinoksalinovi kinase inhibitors
[8]ページ先頭
©2009-2025 Movatter.jp